Skip to content

Assessment of reproducibility after oral food challenge

Assessment of reproducibility after oral food challenge - Assessment of reproducibility after oral food challenge

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053814
Enrollment
800
Registered
2024-03-11
Start date
2024-03-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food allergy

Interventions

Patients undergo an oral food challenge using commercially available products (primary diagnosis) and ingest the same commercially available products at home as they ingested in the oral food challeng

Sponsors

NHO Sagamihara National Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Children with a documented food allergy or suspected food allergy to hen's eggs, milk, wheat, peanuts, walnuts, cashews or almonds who consented to undergo an oral food challenge using commercially available products. The target number of participants is approximately 100 for each food antigen, totaling approximately 800 participants.

Exclusion criteria

Exclusion criteria: Decision of ineligibility by a physician.

Design outcomes

Primary

MeasureTime frame
Percentage of symptom occurrence at home.

Secondary

MeasureTime frame
(1) Percentage of positive results in the oral food challenge (primary diagnosis). (2) Percentage of objective symptom occurrence at home. (3) Percentage of occurrence of symptoms associated with each organ at home. (4) Percentage of positive results at the final diagnosis. (5) Percentage of patients who ingested the food at home.

Countries

Japan

Contacts

Public ContactRui Ozeki

NHO Sagamihara National Hospital Department of Allergy, Clinical Research Center for Allergy and Rheumatology

rui.ozeki11@gmail.com042-742-8311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026